The invention offers a novel approach for an early diagnosis of AD. The invention also opens new avenues for developing either NCEs or biologicals interfering with the nitrated Aβ. Antibody-based therapeutic approaches (e.g. passive/active vaccination) are currently been developed. Prophylactic approaches are also conceivable.
On behalf of University of Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
Patent applications are pending in EP, US and Canada. Clinical trials with β-3NTyr10-antibodies are currently in preparation.